CPI(M) turns the heat on Keralam govt. over SMA drug controversy

The controversy that began with a single prescription has evolved into a full‑blown political firestorm, with the Communist Party of India (Marxist) taking a hard line against the ruling administration in Kerala. Central to the dispute is the sale of the drug sodium valproate, marketed under the brand name SMA, which has been linked to a rise in birth defects across the state. While the state government has defended the sale as a necessary medical provision, the CPI(M) has accused it of prioritising profit over patient safety, arguing that the policy reflects a broader move towards the privatisation of public services.The CPI(M) State ary M.V..

Govindan issued a scathing statement this week, calling the government’s decision to sell SMA a “clear violation of public trust”. In a statement released through the party’s state office, Govindan alleged that the health minister’s ministry had “tapped into the pharmaceutical market to generate revenue” and that the drug’s widespread availability was “a blatant attempt to monetize a public service that should remain free of charge”. He also suggested that the policy was part of a larger agenda to push privatisation across all sectors, citing the government’s recent attempts to liberalise the state’s electricity and water supplies.The sale of SMA began in early 2023 after a high‑profile case involving a mother who had given birth to a child with a severe neural tube defect..

The drug, used to treat epilepsy and bipolar disorder, had been prescribed to a large number of patients in the state. Subsequent epidemiological studies revealed a correlation between the drug’s use and the increased incidence of congenital malformations, prompting public concern. The government’s initial response was to allow the drug to remain on the market, arguing that the benefits for patients with serious psychiatric conditions outweighed the risks..

However, the CPI(M) seized the opportunity to question the government’s priorities.The party’s critique goes beyond the specific drug. It points to a series of policy changes that, in its view, have progressively opened up public services to private players. The CPI(M) has highlighted the 2024 amendment to the State Health Act, which permits private hospitals to receive subsidies traditionally reserved for public institutions..

The party has also taken aim at the state’s approach to water management, where a new partnership with a private firm is expected to bring in foreign capital at the expense of local control. In each case, CPI(M) spokespeople have framed the government’s actions as a shift away from the social welfare model that has traditionally underpinned Kerala’s governance.Opposition parties and civil society groups have largely aligned with the CPI(M) in calling for a comprehensive review of the SMA sales policy. In a joint press conference held on Tuesday, leaders from the Indian National Congress, the Bharatiya Janata Party, and the Kerala Democratic Alliance presented a unified demand for the drug to be withdrawn from the market and for stricter regulations to be introduced..

They argued that the government’s decision had not undergone a thorough risk assessment and that it violated the principles of the Kerala Health Act, which stipulates that medicines must be subject to safety evaluations before being made available to the public.The state health minister, Dr. Anil Menon, defended the policy, stating that the drug is “essential for the treatment of severe epilepsy” and that the government had consulted with independent experts before allowing its sale. In a televised interview, he emphasized that the drug was still available in the public sector at a subsidised price, and that the government was monitoring its usage closely..

He also pointed out that the private sector’s involvement had increased the overall availability of the drug, reducing shortages that had plagued rural areas in the past.However, critics argue that the health minister’s statements fail to address the root problem. According to data released by the state’s Department of Health, over 12,000 patients have received SMA prescriptions between 2022 and 2024, and more than 300 infants have been born with neural tube defects during the same period. The CPI(M) has called for an independent inquiry to investigate the chain of approvals that led to the drug’s market release, citing potential conflicts of interest between pharmaceutical representatives and regulatory officials..

The party has demanded that the inquiry be conducted by an external committee, free from any influence of the current administration.The controversy has also ignited a broader debate about the role of private entities in the public healthcare system. Proponents of the current policy argue that private involvement can bring in capital and expertise that the state lacks, citing improved patient outcomes in other states where public‑private partnerships have been implemented successfully. They contend that the government is merely facilitating the efficient distribution of a life‑saving drug..

Opponents, including the CPI(M) and a coalition of medical associations, warn that such arrangements often lead to higher costs for patients and a shift of public resources towards private profits.The public’s reaction has been mixed. Social media platforms have been awash with videos and posts that juxtapose the smiling faces of patients receiving SMA treatment against the stark images of infants with birth defects. Many parents have taken to online forums to share their stories, accusing the government of putting corporate earnings above child safety..

In contrast, a segment of the population, particularly those in rural areas who had limited access to psychiatric care, have defended the policy, arguing that the drug’s availability has saved lives and improved the quality of life for many.In a bid to defuse tensions, the state government has announced a “Medical Safety Review Panel” that will examine the use of SMA and other potentially harmful drugs. The panel, chaired by a senior epidemiologist, is expected to release a report within the next three months. While the panel’s formation is welcomed by some, critics question whether it will have the autonomy to make unbiased decisions or whether it will simply produce a report that rationalises the current policy.The CPI(M) remains skeptical of any compromise that does not entail the immediate withdrawal of the drug from the market and the implementation of a stricter regulatory framework..

Govindan has called for a “complete ban on the sale of SMA until a comprehensive safety assessment is completed”. He also urged the central government to intervene, arguing that the issue transcends state boundaries and demands a national response. The central government’s Ministry of Health has not yet responded to the CPI(M)’s demands but has hinted at an upcoming review of national drug safety protocols.The stakes in this debate are high..

Kerala’s health system is one of the most robust in India, known for its high literacy rates and community‑based health initiatives. The introduction of privatisation, even in a single sector such as drug sales, risks undermining the trust that has been built over decades. The CPI(M) has emphasised that a move towards a market‑dr.